a16z Crypto Leads $7 Million Seed Round for KYD Labs to Drive Blockchain Ticketing Innovation

PANews2025/05/14 13:44

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to CoinDesk, venture capital firm a16z Crypto led a $7 million seed round for blockchain ticketing platform KYD Labs. Built on Solana, KYD aims to empower artists and venues to control ticket sales, fan data, and revenue, addressing the issue of revenue loss from secondary market circulation. It is reported that after using the KYD system, ticket revenue for the well-known New York venue LPR increased by 30%. KYD plans to expand to over 100 U.S. venues by 2026 and launch two tokens, $KYD and $TIX, to strengthen the community and financial foundation.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

WTI Price Forecast: Slides further below $100.50; bullish potential seems intact

FXStreet•2026/10/26 05:33

European morning quotes - Elections, central bank policies, and earnings reports will be in focus

路透社•2026/10/26 04:41

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20